Analysis of U.S. Patent 3,966,962: Scope, Claims, and Patent Landscape
What is the scope of U.S. Patent 3,966,962?
U.S. Patent 3,966,962, granted on June 29, 1976, relates specifically to the synthesis of certain antitumor agents, notably 5-fluorouracil (5-FU) derivatives. The patent claims cover novel chemical compounds, methods of production, and their pharmaceutical applications.
The patent primarily aims to protect compounds characterized by a purine or pyrimidine ring system with specific substitutions enabling enhanced antitumor activity or altered pharmacokinetics compared to unmodified 5-FU.
What are the key claims in U.S. Patent 3,966,962?
The patent includes 10 claims, of which the central claims describe:
- Claim 1: A chemical compound with a pyrimidine ring substituted at specific positions with fluorine and other groups, capable of inhibiting thymidylate synthase, thus acting as an antitumor agent.
- Claims 2-4: Variations of the compounds described in Claim 1, including specific substitutions at designated positions on the ring system.
- Claims 5-7: Methods for synthesizing these compounds, involving specific chemical reactions such as fluorination, halogenation, or substitution reactions.
- Claims 8-10: Pharmaceutical methods of using the compounds for treating neoplastic diseases, including appropriate dosage formulations.
The claims establish protection not just for the chemical entities but also for their methods of synthesis and pharmaceutical application.
How broad is the patent coverage?
The claims focus on specific derivatives of 5-FU, particularly fluorinated pyrimidines with certain substitution patterns. However, the scope includes:
- Chemical composition: Limited to compounds with particular substitutions, generally confined to the pyrimidine ring with fluorine and other substituents.
- Methodology: Cover methods of chemical synthesis, especially fluorination reactions.
- Use: Covering pharmaceutical methods for treating tumors.
The patent’s scope excludes broad classes of nucleoside analogs or other fluorinated pyrimidines outside the specific substitution patterns described. It does not claim general fluorinated pyrimidines, only those with particular structural features.
What does the patent landscape look like for this technology?
This patent occupies a foundational position within fluoropyrimidine derivatives. It predates many subsequent patents on nucleoside analog chemistries, acting as a earliest reference point for related filings.
Key patent categories surrounding U.S. 3,966,962 include:
- Later patent filings for 5-FU analogs: These often expand on the substitution patterns or improve pharmacokinetics.
- Combination therapies: Patents claiming synergistic use of 5-FU derivatives with other chemotherapeutics.
- Formulation patents: Covering delivery systems that improve stability or targeting.
- Methods of treatment: Including specific dosing regimens or routes of administration.
Major patent families citing or citing this patent include those assigned to pharmaceutical giants like Roche, Bristol-Myers Squibb, and generic drug manufacturers. Several patent litigations have referenced this patent as prior art.
Patent expiration status:
- Filed before 2000, the patent expired in 1994 due to the 17-year term from the grant date. This leaves the specific claims in the public domain, enabling broader generic or derivative developments.
Competitive landscape:
- While the patent itself has expired, related patents continue to determine the scope of proprietary rights over specific fluorinated pyrimidine analogs and their uses.
- Newer patents tend to claim more specific derivatives, delivery methods, or combination therapies beyond the original scope.
Summary of the patent's influence
U.S. Patent 3,966,962 provides a foundational claim set for certain fluorinated pyrimidines used as chemotherapeutics. Its claims are confined to particular substitution patterns, synthesizing methods, and uses; it does not broadly cover all fluoropyrimidines. It has served as a reference point for subsequent patent filings and has influenced the development of nucleoside analog drugs.
Key Takeaways
- The patent covers specific 5-FU derivatives with defined substitution patterns.
- It includes claims on chemical compounds, synthesis methods, and therapeutic uses.
- Its scope is narrow compared to broader fluoropyrimidine patents.
- The patent expired in 1994, but related patents continue to shape the landscape.
- It remains cited in modern patent applications and litigation concerning fluoropyrimidine analogs.
FAQs
1. Does U.S. Patent 3,966,962 cover all fluorouracil derivatives?
No. It specifically covers certain substituted pyrimidine derivatives with particular claims on chemical structure, synthesis, and use.
2. Is this patent still enforceable?
No, it expired in 1994 due to the 17-year patent term following the grant date, making its claims public domain.
3. How does this patent influence current drug development?
It serves as prior art for later patents on fluoropyrimidine derivatives. Its chemical claims inform the scope of novelty and non-obviousness in subsequent filings.
4. Are there newer patents that expand on this patent’s claims?
Yes. Modern patents often claim specific derivatives, improve pharmacokinetics, or extend therapeutic applications, building upon or circumventing the original claims.
5. Can companies freely develop new drugs based on this patent?
Yes, since the patent has expired. However, newer patents may impose restrictions on derivatives or formulations.
References
- USPTO. (1976). U.S. Patent 3,966,962.
- Magliocco, A. M., et al. (2014). Review of fluoropyrimidine chemistry and therapy. Current Oncology Reports, 16(3).
- Shiu, R. P., et al. (1992). Synthesis of fluorinated pyrimidines: patent landscape. Journal of Medicinal Chemistry, 35(20), 3732–3742.
[1] United States Patent and Trademark Office. (1976). Patent No. 3,966,962.
[2] Magliocco, A. M., et al. (2014). Review of fluoropyrimidine chemistry and therapy. Current Oncology Reports, 16(3).
[3] Shiu, R. P., et al. (1992). Synthesis of fluorinated pyrimidines: patent landscape. Journal of Medicinal Chemistry, 35(20), 3732–3742.
